Timing of B-cell maturation antigen (BCMA)-targeting treatment
| Treatments . | Total cilta-cel N = 18∗ . | |
|---|---|---|
| Responders n = 12 . | Nonresponders n = 6 . | |
| Duration of last anti-BCMA treatment, days | ||
| Median | 29.5 | 63.5 |
| Range | 1-277 | 22-527 |
| Time from last anti-BCMA treatment to apheresis, days | ||
| Median | 161.0 | 56.5 |
| Range | 26-695 | 40-895 |
| Time from last anti-BCMA treatment and cilta-cel infusion, days | ||
| Median | 235.0 | 117.5 |
| Range | 62-749 | 95-944 |
| Treatments . | Total cilta-cel N = 18∗ . | |
|---|---|---|
| Responders n = 12 . | Nonresponders n = 6 . | |
| Duration of last anti-BCMA treatment, days | ||
| Median | 29.5 | 63.5 |
| Range | 1-277 | 22-527 |
| Time from last anti-BCMA treatment to apheresis, days | ||
| Median | 161.0 | 56.5 |
| Range | 26-695 | 40-895 |
| Time from last anti-BCMA treatment and cilta-cel infusion, days | ||
| Median | 235.0 | 117.5 |
| Range | 62-749 | 95-944 |
Two patients died before confirmed disease evaluations and were excluded from the analysis.